Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
Current Oncology (Toronto, Ont.)|February 28, 2013
Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statementK I Pritchard, K A Gelmon, D Rayson, et al.Talanta|October 31, 2008
Impact of filter paper on fluorescence measurements of buffered saline filtratesTimothy L Danielson, Gary D Rayson, Dean M Anderson, et al.Applied Spectroscopy|July 21, 2006
Photoluminescent distinction among plant life forms using phosphate buffered saline extract solutionsTimothy L Danielson, Safwan Obeidat, Gary D Rayson, et al.Applied Spectroscopy|March 15, 2008
A multi-source portable light emitting diode spectrofluorometerSafwan Obeidat, Baolong Bai, Gary D Rayson, et al.Cancer|November 7, 1998
Molecular markers in male breast carcinomaD Rayson, C Erlichman, V J Suman, et al.Implementation Science : IS|February 14, 2019
The role of scientific evidence in decisions to adopt complex innovations in cancer care settings: a multiple case study in Nova Scotia, CanadaR Urquhart, C Kendell, L Geldenhuys, et al.Current Oncology (Toronto, Ont.)|August 13, 2009
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerS Dent, Sh Verma, J Latreille, et al.Clinical Genetics|November 18, 2009
Identifying mental health services in clinical genetic settingsM Cappelli, M J Esplen, B J Wilson, et al.Current Oncology (Toronto, Ont.)|October 29, 2009
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancersJ Lemieux, M Clemons, L Provencher, et al.Current Oncology (Toronto, Ont.)|August 11, 2010
Optimizing the management of HER2-positive early breast cancer: the clinical realitySu Verma, S Lavasani, J Mackey, et al.Pageof 5